Evidence map›Paper›PMID 33398412›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2021

[

Gaetan Van Simaeys, Gilles Doumont, Coraline De Maeseneire, Nicolas Passon, Simon Lacroix, Cédric Lentz, Arnaud Horion, Corentin Warnier, David Torres, Corentin Martens and 3 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Fully Automated Production of (((Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  2. Preclinical Imaging of Prostate Cancer.Seminars in nuclear medicine · 2023
    Review
  3. Article
  4. Clinical experience withEuropean journal of hybrid imaging · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Gaetan Van SimaeysCenter for Microscopy and Molecular Imaging, Université libre de Bruxelles, Charleroi, Belgium. gaetan.vansimaeys@ulb.ac.be.ORCID https://orcid.org/0000-0002-2678-542X
Gilles DoumontCenter for Microscopy and Molecular Imaging, Université libre de Bruxelles, Charleroi, Belgium.
Coraline De MaeseneireCenter for Microscopy and Molecular Imaging, Université libre de Bruxelles, Charleroi, Belgium.
Nicolas PassonCenter for Microscopy and Molecular Imaging, Université libre de Bruxelles, Charleroi, Belgium.
Simon LacroixCenter for Microscopy and Molecular Imaging, Université libre de Bruxelles, Charleroi, Belgium.
Cédric LentzTrasis SA, Liège, Belgium.
Arnaud HorionTrasis SA, Liège, Belgium.
Corentin WarnierTrasis SA, Liège, Belgium.
David TorresInstitute for Medical Immunology, Université libre de Bruxelles, Charleroi, Belgium.
Corentin MartensCenter for Microscopy and Molecular Imaging, Université libre de Bruxelles, Charleroi, Belgium.
Irina VierasuService de médecine nucléaire, Hôpital Érasme, Université libre de Bruxelles, Brussels, Belgium.
Dominique EgriseCenter for Microscopy and Molecular Imaging, Université libre de Bruxelles, Charleroi, Belgium.
Serge GoldmanCenter for Microscopy and Molecular Imaging, Université libre de Bruxelles, Charleroi, Belgium.ORCID https://orcid.org/0000-0002-9917-8735
Université Libre de Bruxelles · BE

Funding

Fonds pour la Formation à la Recherche dans l'Industrie et dans l'Agriculture (BE) 5120417FWalloon Region C-7559Walloon Region (BE) C-7559
6 · The paper itself

Abstract

purposeThis preclinical study aims to evaluate the extent to which a change in prostate-specific membrane antigen (PSMA) expression of castration-resistant prostate cancer (CRPC) following standard treatment is reflected in [

methodsCastrated mice supplemented with testosterone implant were xenografted with human LNCaP CRPC. After appropriate tumour growth, androgen deprivation therapy (ADT) was carried out by the removal of the implant followed by a single injection of docetaxel (400 μg/20-g mouse) 2 weeks later. [

resultsADT alone had no early effect on LNCaP tumours that pursued their progression. Until day 12 post-docetaxel, the [

conclusionApplying PSMA-based imaging for therapy monitoring in patients with CRPC should be considered with caution since a reduction in [

Indexed as

Prostatic NeoplasmsAndrogen AntagonistsAnimalsFluorodeoxyglucose F18HeterograftsHumansMaleMicePositron Emission Tomography Computed TomographyAndrogen AntagonistsFluorodeoxyglucose F18ImagingPositron emission tomographyPreclinical modelProstate carcinomaPSMA

Identifiers

PMID33398412
OpenAlexW3120765968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.